Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies

NCT07730125 is registered in ClinicalTrials.gov with CoRegen, Inc. as lead sponsor.

NCT NCT07730125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07730125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
Lead sponsor
CoRegen, Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
June 30, 2030
Enrollment
67 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hr-positive, her2-negative breast cancer, prostate cancer, tnbc - triple-negative breast cancer